Sen. Rick Scott (R-Fla.) warned on July 28, 2026, that new regulatory rules implemented by the Chinese government could threaten U.S. pharmaceutical supply chains and increase risks for American companies. Scott argued that these measures are designed to maintain U.S. dependence on Beijing for critical medicines while penalizing companies that attempt to diversify their manufacturing bases or comply with U.S. laws.

The Florida Republican stated that the new rules restrict the ability of U.S. regulators, including the Food and Drug Administration (FDA), to access information about medicines produced in China. "They say the FDA can’t know about drugs that are made in China. Oh, but they want to sell them to us, right?" Scott said in a post on X, questioning the intentions behind the decree.

Scott accused Beijing of pressuring U.S. companies that follow American laws or try to move production out of China. "China’s government passed new rules that harm U.S. companies who comply with U.S law or try to move production out of China," he wrote. He emphasized that American firms should not be allowed to remain dependent on Chinese manufacturing for essential goods.

Call for Domestic Production

The senator called for a strategic shift toward domestic manufacturing to mitigate national security and supply chain risks. "We need to bring all of production of drugs back into this country and we need to stop being dependent on Communist China for anything, especially any drugs," Scott said.

This warning follows heightened scrutiny from U.S. lawmakers regarding biotechnology security risks associated with clinical trials in China. In June, a bipartisan group of lawmakers investigated Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) over concerns that trials conducted at Xinjiang facilities and military-affiliated hospitals could expose sensitive research data.

Lawmakers had requested details on data protection and oversight practices from these companies, warning that lack of transparency could pose significant security threats. The investigation highlights growing political pressure on pharmaceutical giants to reconsider their operational footprint in China.

Trade Context

Despite recent tensions, China had reportedly eased some trade restrictions last year by exempting certain U.S. imports, including pharmaceutical and aerospace products, from high tariffs. Chinese officials sought feedback from companies on additional goods that could qualify for such exemptions.

However, Scott’s comments suggest that regulatory opacity and potential data access restrictions may outweigh tariff relief for U.S. stakeholders. The senator’s stance aligns with broader efforts by U.S. policymakers to reduce reliance on foreign adversaries for critical medical supplies.

Senator Rick Scott warned that artificial intelligence is accelerating new national security risks and introduced legislation requiring mandatory federal reporting on how terrorist groups may be using generative AI tools. The proposed Generative AI Terrorism Risk Assessment Act mandates that the federal government issue regular, public reports assessing how terror organizations could leverage AI technologies. Scott stated the goal is to ensure policymakers and the public are putting out regular, public threat assessments on how terror groups are using AI.

AI Security Crackdown Grows

Federal officials have heightened their focus on AI-related security threats. FBI Director Kash Patel ordered counterterrorism teams to remain on high alert, noting that federal units were fully engaged on overseas situations and Joint Terrorism Task Forces were working 24/7 to disrupt potential threats. Department of Homeland Security Secretary Kristi Noem said she was coordinating with federal partners to monitor and prevent risks to the homeland.

State and Private Sector Actions

State governments and private entities are also implementing safeguards. California Governor Gavin Newsom signed an executive order requiring companies seeking state contracts to adopt safeguards against AI misuse and mandating watermarks on AI-generated images and videos to reduce misinformation and deepfakes. The Pentagon designated Anthropic as a supply-chain risk, limiting its use in military-related contracting. Perplexity AI CEO Aravind Srinivas cautioned users against abusing AI tools after a viral video showed the company's Comet browser completing a Coursera assignment in seconds.